Navigation Links
EUSA Pharma Completes Acquisition Of Cytogen Corporation
Date:5/9/2008

DOYLESTOWN, Pennsylvania and OXFORD, England, May 9 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has completed its acquisition of Cytogen Corporation, following the approval of Cytogen's shareholders at a special meeting on 8 May.

Under the terms of the acquisition agreement, Cytogen shareholders will receive $0.62 per share, valuing the company at $22.6 million. To meet the consideration, EUSA has raised over $50 million in an investment round led by TVM Capital and supported by EUSA's existing investors, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. EUSA will now apply to delist all Cytogen's issued shares from the NASDAQ stock exchange.

Cytogen brings to EUSA three oncology and pain control products, a US specialty sales force and an established commercial infrastructure. With the completion of the acquisition, Cytogen will form a wholly-owned subsidiary of EUSA and will operate under the EUSA name.

"Completing our acquisition of Cytogen is particularly significant for EUSA as it also completes our transatlantic growth platform, positioning us as a partner of choice for further acquisitions and product in-licensing," said Bryan Morton, Chief Executive of EUSA Pharma. "We now have a strong US commercialization infrastructure to match our organization in Europe, which covers over 20 countries. We plan to rapidly integrate the Cytogen organization, allowing us to compete with major players as we accelerate our search for additional specialty products to leverage our infrastructure on both sides of the Atlantic. With a growing portfolio of medicines, we plan to begin exploiting our transatlantic platform with the launch of our US product Caphosol(R) in several European territories."

About EUSA Pharma Inc

EUSA Pharma is a rapidly growing transatlantic
'/>"/>

SOURCE EUSA Pharma Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Calif. , April 21, 2015 /PRNewswire/ ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... announced that Dr. Mark W. Sawicki ... the 3rd Annual BioLogistics Summit in ...
(Date:4/21/2015)... SYDNEY , April 21, 2015  Novogen Limited ... Australian/US biotechnology company, advises that it has entered ... million fully-paid ordinary shares plus one attaching 6-month ... for every ordinary share issued, to institutional investors ... in a private placement for aggregate gross proceeds ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Progyny, Inc., ... Authority, LLC, announced that it has secured additional capital ... TPG Biotech, SR One and Merck Serono Ventures. The ... provide patients the best fertility outcomes by aligning science, ... largest online marketplace for families seeking fertility solutions and ...
(Date:4/21/2015)... DIEGO, CA (PRWEB) April 21, 2015 Whether ... in a lab, or bolted to a Kessler CineDrive ... stadium… or at the beach, the TS3-H is designed to ... Based on a brand-new state-of-the-art 5MP sensor, the TS5-H offers ... predecessors, with superior imaging characteristics. , According to Tom ...
Breaking Biology Technology:Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 3
...  AMPAC Fine Chemicals LLC (AFC), a wholly-owned ... has concluded an agreement with Chimerix, Inc. to validate ... in Chimerix,s broad spectrum antiviral drug candidate, CMX001, which ... smallpox.  Chimerix will provide the investigational drug product under ...
... FORT LEE, N.J., Aug. 11, 2011 Neurologix, ... of innovative gene therapies for disorders of the brain and ... three and six months ended June 30, 2011. ... a net loss of approximately $3.0 million, as compared with ...
... Genetics, Inc. (OTCQB: ILIU) announced today that CEO Lewis ... Management Access Conference at the Le Parker Meridien Hotel, 119 ... scheduled for Wednesday, Aug. 17 at 3:35 p.m. (EDT) in ... Interleukin,s management team will be available for one-on-one meetings ...
Cached Biology Technology:AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 2AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 3AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 4Neurologix Announces Second Quarter 2011 Financial Results 2Neurologix Announces Second Quarter 2011 Financial Results 3Neurologix Announces Second Quarter 2011 Financial Results 4Neurologix Announces Second Quarter 2011 Financial Results 5Neurologix Announces Second Quarter 2011 Financial Results 6Neurologix Announces Second Quarter 2011 Financial Results 7Neurologix Announces Second Quarter 2011 Financial Results 8Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference 2
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced ... Strategic Business Report" report to their offering. This ... US$ Thousands by the following Segments: Face Biometrics, and Voice Biometrics. ... Canada , Japan , Europe ... & Africa , and ...
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... a group of plant viruses that cause devastating disease ... with The American Phytopathological Society (APS). , According ... University of Arizona's Department of Plant Sciences, the whitefly, ... (transmitter) for a large group of emerging plant viruses ...
... around the world die of this type of meningitis, according ... the disease is called, can even spark epidemics: in Africa ... the late 1990s. Without treatment, mortality among those who ... percent. Patients also run a high risk of serious ...
... But exactly what our tears are made of has remained a ... the complex design of tears. What we think of as tears, ... microscopic layers. The middle, watery layer ?what we normally think of ... mucus and an outer layer of fatty, oily substances collectively called ...
Cached Biology News:Tears reveal some of their deepest secrets to researchers 2Tears reveal some of their deepest secrets to researchers 3
Reacts with methylated DNA from plants and vertebrates...
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
WTAP Antibody...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Biology Products: